Absci (ABSI) Cash & Current Investments (2020 - 2026)
Absci (ABSI) posted Cash & Current Investments of $125.7 million for Q1 2026, down 12.88% sequentially from $144.3 million in Q4 2025, and down 6.18% YoY from $134.0 million in Q1 2025.
Analysis
Absci (ABSI) Cash & Current Investments (2020 - 2026) Analysis & Trends
Absci has reported Cash & Current Investments for 7 years, with the latest figure at $125.7 million in Q1 2026.
- Quarterly Cash & Current Investments fell 6.18% year-over-year to $125.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $125.7 million (down 6.18% YoY) and the FY2025 annual result came in at $144.3 million, up 28.35% from the prior year.
- Cash & Current Investments retreated to $125.7 million in Q1 2026 per ABSI's latest filing, from $144.3 million in the prior quarter.
- Over five years, Cash & Current Investments peaked at $226.0 million in Q1 2022 and troughed at $50.0 million in Q2 2022.
- A 5-year average of $136.6 million and a median of $134.0 million in 2025 frame the typical range for Cash & Current Investments.
- The sharpest annual moves came in 2022 and 2023: Cash & Current Investments sank 49.72% in 2022, then jumped 149.16% in 2023.
- Over 5 years, Cash & Current Investments stood at $164.4 million in 2022, then plunged by 40.61% to $97.7 million in 2023, then grew by 15.12% to $112.4 million in 2024, then advanced by 28.35% to $144.3 million in 2025, then dropped by 12.88% to $125.7 million in 2026.
- According to Business Quant data, Cash & Current Investments over the past three periods registered $125.7 million, $144.3 million, and $152.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.74 Bn | 130.89 Bn | 2.84 Bn | 7.85 Bn |
| 2 | Regeneron Pharmaceuticals | 85.52 Bn | 77.52 Bn | 3.93 Bn | 7.99 Bn |
| 3 | Argenx Se | 63.51 Bn | 58.32 Bn | 1.37 Bn | 5.18 Bn |
| 4 | Moderna | 58.04 Bn | 52.91 Bn | 52.00 Mn | 5.14 Bn |
| 5 | Revolution Medicines | 44.06 Bn | 44.06 Bn | - | - |
| 6 | BeOne Medicines | 39.98 Bn | 34.88 Bn | 1.53 Bn | 5.10 Bn |
| 7 | Alnylam Pharmaceuticals | 35.46 Bn | 32.15 Bn | 992.69 Mn | 3.31 Bn |
| 8 | Royalty Pharma | 28.41 Bn | 27.57 Bn | - | 836.99 Mn |
| 9 | Insmed | 27.44 Bn | 26.28 Bn | 358.27 Mn | 1.16 Bn |
| 10 | Absci | 1.39 Bn | 1.19 Bn | - | 201.14 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 201.14 Mn |
| Mar 31, 2026 | 125.71 Mn |
| Dec 31, 2025 | 144.29 Mn |
| Sep 30, 2025 | 152.48 Mn |
| Jun 30, 2025 | 117.46 Mn |
| Mar 31, 2025 | 133.98 Mn |
| Dec 31, 2024 | 112.43 Mn |
| Sep 30, 2024 | 127.07 Mn |
| Jun 30, 2024 | 145.25 Mn |
| Mar 31, 2024 | 161.54 Mn |
| Dec 31, 2023 | 97.66 Mn |
| Sep 30, 2023 | 113.48 Mn |
| Jun 30, 2023 | 124.59 Mn |
| Mar 31, 2023 | 144.26 Mn |
| Dec 31, 2022 | 164.43 Mn |
| Sep 30, 2022 | 181.31 Mn |
| Jun 30, 2022 | 206.02 Mn |
| Mar 31, 2022 | 226.00 Mn |
| Dec 31, 2021 | 252.57 Mn |
| Sep 30, 2021 | 279.26 Mn |